Variant · Fusion
NFIB Fusion
CI-VAR-00001442Explore in graph →CIViC 5051
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28954282
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| DOID:00802023unmapped disease | ||||||||
| MYB::NFIB Fusion | Linsitinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12164In a study of oncogenic signalling pathways, tumours and cultured cells from 15 patients with MYB-NFIB translocation-positive adenoid cystic carcinoma (ACC) were analyzed. Treatment with linsitinib, a… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC | civic |
| MYB::NFIB Fusion | Crizotinib + Gefitinib + LinsitinibCombination | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID12167Treatment of ACC cells with a combination of linsitinib, crizotinib, and gefitinib resulted in synergistic inhibition of cell proliferation (p = 0.004). This combination also significantly downregulat… (full text at CIViC) PMID 28954282 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available